Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday the Directors below purchased ordinary shares of 25 pence in the Company.
| Director | No of Ordinary Shares purchased
|
Price paid | Resultant shareholding
|
% of the issued share capital |
| Dr Michael Sinclair, Executive Chairman | 100,000 | 28.35p | 4,728,229 | 6.51% |
| Dr Enrico Vanni, Non-Executive Director | 100,000 | 28.50p | 923,946 | 1.27% |
| Advanced Oncotherapy Plc | www.avoplc.com |
| Dr. Michael Sinclair, Executive Chairman | Tel: +44 20 3617 8728 |
| Nicolas Serandour, CEO | |
| Stockdale Securities (Nomad & Joint Broker) | |
| Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
| Stifel Nicolaus Europe (Joint Broker) | |
| Jonathan Senior / Ben Maddison | Tel: +44 20 7710 7600 |
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
| Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.